Anti-Coagulants - Madagascar

Madagascar

The Anti-Coagulants market in Madagascar is expected to witness a significant increase in revenue in the coming years.
By 2024, the projected revenue is estimated to reach US$1.70m.
This growth is anticipated to continue with an annual growth rate of 8.36%, resulting in a market volume of US$2.54m by 2029.
When compared to other countries, United States is projected to generate the highest revenue in the Anti-Coagulants market.
In 2024, the revenue United States is expected to reach a staggering US$16,740.00m.
Madagascar's anti-coagulant market is witnessing a surge in demand due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Madagascar is experiencing a steady growth rate in recent years.

Customer preferences: Madagascar has a high prevalence of cardiovascular diseases, which has led to an increase in the demand for anti-coagulants. Patients are increasingly opting for anti-coagulants to prevent blood clots, which can lead to heart attacks or strokes. Additionally, the aging population in Madagascar has also contributed to the growth of the anti-coagulants market.

Trends in the market: The Anti-Coagulants market in Madagascar is dominated by oral anticoagulants, which are preferred by patients due to their ease of use. The market is also witnessing the introduction of new drugs, which are more effective and have fewer side effects. Manufacturers are investing in research and development to introduce new drugs that can cater to the specific needs of the local population.

Local special circumstances: Madagascar has a high prevalence of malaria, which has led to the development of a drug-resistant strain of the disease. This has resulted in the increased use of anti-coagulants as a treatment for malaria. Additionally, the lack of access to healthcare facilities in rural areas has led to an increase in demand for over-the-counter anti-coagulants.

Underlying macroeconomic factors: Madagascar is one of the poorest countries in the world, with a large portion of the population living below the poverty line. This has led to the government's inability to invest in healthcare infrastructure, leading to a lack of access to healthcare facilities in rural areas. Additionally, the country's economy is heavily dependent on agriculture, which has been affected by climate change and natural disasters. This has resulted in a lack of funds for the healthcare sector, leading to a reliance on foreign aid.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.